Business
Announcement on Voluntary Disclosure of Completion of the 1st Subject Enrollment in Phase I Clinical Trial of FZ-AD005 Antibody-drug Conjugate for Injection in the Treatment of Advanced Solid Tumors
Announcement on Voluntary Disclosure of Completion of the 1st Subject Enrollment in Phase I Clinical Trial of FZ-AD005 Antibody-drug Conjugate for Injection in the Treatment of Advanced Solid Tumors
About this update from Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A
Announcement on Voluntary Disclosure of Completion of the 1st Subject Enrollment in Phase I Clinical Trial of FZ-AD005 Antibody-drug Conjugate for Injection in the Treatment of Advanced Solid TumorsThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment